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Analysis of 2668 children with acute lymphoblastic leukemia
(ALL) treated in two successive Nordic clinical trials (Nordic
Society of Paediatric Haematology and Oncology (NOPHO)
ALL-92 and ALL-2000) showed that 75% of all patients are cured
by first-line therapy, and 83% are long-term survivors. Improve-
ments in systemic and intrathecal chemotherapy have reduced
the use of central nervous system (CNS) irradiation too10% of
the patients and provided a 5-year risk of isolated CNS relapse
of 2.6%. Improved risk stratification and chemotherapy have
eliminated the previous independent prognostic significance of
gender, CNS leukemia and translocation t(1;19)(q23;p13),
whereas the post-induction level of minimal residual disease
(MRD) has emerged as a new risk grouping feature. Infant
leukemia, high leukocyte count, T-lineage immunophenotype,
translocation t(4;11)(q21;q23) and hypodiploidy persist to be
associated with lower cure rates. To reduce the overall toxicity
of the treatment, including the risk of therapy-related second
malignant neoplasms, the current NOPHO ALL-2008 protocol
does not include CNS irradiation in first remission, the dose of
6-mercaptopurine is reduced for patients with low thiopurine
methyltransferase activity, and the protocol restricts the use of
hematopoietic stem cell transplantation in first remission to
patients without morphological remission after induction
therapy or with high levels of MRD after 3 months of therapy.
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Introduction
Better understanding of the disease biology and the pharmacol-
ogy of anticancer agents as well as performance of randomized
clinical trials have dramatically improved the cure rates of
childhood acute lymphoblastic leukemia (ALL).1,2 In 1981, the
Nordic Society of Paediatric Haematology and Oncology
(NOPHO) started a common registration of all children below
15 years of age at diagnosis of ALL in the five Nordic countries
(Denmark, Finland, Iceland, Norway and Sweden).3 During the
following decade the therapy became harmonized, and since
January 1992 Nordic children 1.0–14.9 years of age have been
treated according to common protocols. The details and
treatment results of two previous non-uniform protocol periods
1981–1985 and 1986–1991 were reported in the December
2000 issue of Leukemia together with those of 11 other study
groups,4 and their overall results are presented in Table 1.
The goals of the first common NOPHO protocol (NOPHO
ALL-92) were to replace cranial irradiation with intravenous
high-dose chemotherapy for all but the highest risk patients, to
examine in detail the significance of oral methotrexate (MTX)/6-
mercaptopurine (6MP) maintenance therapy, and to centrally
and prospectively scrutinize the karyotypes of all patients. The
study showed the feasibility of reduced use of cranial irradia-
tion,4 emphasized that host pharmacogenetics influence the
cure rate,5 confirmed the importance of myelosuppression
during maintenance therapy,6 showed that MTX/6MP main-
tenance therapy is important for high-risk (HR) ALL,7 and
allowed mapping of the epidemiological and clinical characte-
ristics of several cytogenetically defined subsets of ALL.8–14 The
goals of the subsequent common NOPHO ALL-2000 protocol
were to examine the efficacy of Vincristine (VCR)/Dexametha-
sone reinductions during maintenance therapy and to examine
the feasibility of non-centralized minimal residual disease
(MRD) monitoring by flow cytometry and PCR.15–19 The ALL-
92 and ALL-2000 studies have paved the way to total
elimination of prophylactic cranial irradiation in the current
ALL-2008 protocol and to implementation of a treatment
stratification primarily based on cytogenetics and early MRD
monitoring. We here present the results of the NOPHO ALL-92
and ALL-2000 studies and our current strategy for treatment of
childhood ALL. In recent years, infants with ALL have been
treated according to the Interfant protocols,20 and patients with
translocation t(9;22)(q34;q11) have been treated according to
the international EsPhALL protocol for Philadelphia-positive
childhood ALL.
Materials and methods
From January 1992 to December 2007, 2668 children 1.0–14.9
years of age were diagnosed with B-cell precursor or T-cell ALL
in the Nordic countries and enrolled in the ALL-92 protocol
(1992 to 2001, N¼ 1645) or the ALL-2000 protocol (2002 to
2007, N¼ 1023). The diagnosis of ALL was based on
morphologic evaluation of bone marrow smears in combination
with immunophenotyping with panels of monoclonal antibodies
directed toward lineage-associated antigens. Patients with
mature B-ALL have been treated according to mature B-cell
non-Hodgkin lymphoma protocols, and they are excluded from
this report. Only G-band karyotyping was mandatory in the ALL-
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92 protocol, but the ALL-2000 protocol also required directed
analysis by fluorescent in situ hybridization and/or reverse
transcriptase PCR for translocations t(9;22)(q34;q11)(BCR–ABL)
or t(1;19)(q23;p13)(E2A–PBX1), and for 11q23/MLL aberrations.
Furthermore, many leukemic samples have been examined by
comparative genomic hybridization, spectral karyotyping and
DNA-index by flow cytometry, and nearly all patients have in
recent years been examined for the t(12;21)(ETV6–RUNX1)
translocation, although the presence of this translocation does
not influence the treatment stratification.9 All cytogenetic results
are scrutinized annually by the NOPHO cytogenetic working
group and described according to ISCN 1995.21 The protocols
were approved by the regional or national ethics committees,
and informed consent was obtained according to the Declara-
tion of Helsinki.
Risk grouping and treatment
NOPHO ALL-92 risk grouping
Details of the NOPHO ALL-92 protocol have been described in
previous publications.4,6,22 The risk group assignment was
based on age and white blood cell count (WBC) at diagnosis
(standard risk (SR): age 2.0–9.9 years and WBC o10.0 109/l;
intermediate risk (IR): age 1.0–1.9 or X10.0 years and/or WBC
10–49.9 109/l; higher risk (that is, HR or very high risk (VHR)):
WBCX50.0 109/l) and the presence of higher risk features: T-
lineage ALL, the presence of CNS or testicular involvement,
translocations t(9;22)(q34;q11) or t(4;11)(q21;q23), lymphoma-
tous leukemia or mediastinal lymphoma, and/or a poor
treatment response (M3 BM at day 15 or M2/M3 at day 29).4
Patients who had higher risk features were assigned to the VHR
treatment arm, if they were at least 5 years of age at diagnosis
(because of the use of cranial irradiation in that protocol arm)
and in addition had (i) T-cell disease with one or more
additional HR-features, (ii) CNS leukemia, (iii) lymphomatous
leukemia and/or (iv) higher risk ALL at diagnosis and a day 15
M3 or a day 29 M2/M3 bone marrow.
NOPHO ALL-92 therapy
Induction therapy. All patients received Prednisolone
(60 mg/m2/day on days 1–36, then tapered), weekly VCR
(2.0 mg/m2 six times, maximum 2.0 mg), Doxorubicin (40 mg/m2
three times (SR and IR) or four times (HR)), Erwinia asparaginase
(30.000 IU/m2 daily on days 37–46) and intrathecal (i.t.) MTX on
four occasions.
Early intensification. Immediately after induction therapy,
IR- and HR-patients received two doses of Cyclophosphamide
(1000 mg/m2 two times, 4 weeks apart) with low-dose
Cytarabine (75 mg/m2 daily for two 4-day periods after each
Cyclophosphamide dose) and oral 6MP.
Consolidation. For SR–ALL, consolidation therapy included
three courses of high-dose MTX (HD–MTX) 5 g/m2/24 h with i.t.
MTX and Leucovorin rescue. Patients with IR–ALL received oral
6MP (25 mg/m2/day) with four courses of HD–MTX 5 g/m2/24 h
with i.t. MTX and Leucovorin rescue at 2 weeks intervals,
whereas patients with HR– or VHR–ALL received HD–MTX
8 g/m2/24 h with i.t. MTX and Leucovorin rescue, alternating
with high-dose Cytarabine (12 g/m2) two times (VHR) or four
times (HR) with two 2-month intervening periods of oral weekly
MTX and daily 6MP with two VCR/Prednisolone reinductions
per period.
Table 1 Treatment outcome according to NOPHO ALL study periods
NOPHO protocol periods Non-uniform Non-uniform ALL-92 ALL-2000
Year 1981–1985 1986–1991 1992–2001 2002–2007
No. of patients 719 937 1645 1023
Induction deatha 36 16 21 16
Resistant diseasea 9 14
Complete remission 375 627 1223 848
Relapses
Hematologic only 145 164 214 80
CNS only 62 35 44 24
Hematologic+CNS 42 23 33 14
Testicular only 23 20 14 2
Hematologic+testis 8 10 15 0
Hematologic+CNS+testis 2 1 1 0
Other relapses sites 5 11 14 6
Second cancer 6 15 21 4
Death in first remission 13 14 34 15
10-year cumulative remission death 0.02±0.01 0.01±0.0 0.02±0.0 F
5-year EFS±s.e. 0.56±0.02 0.70±0.02 0.77±0.01 0.79±0.02
10-year EFS±s.e. 0.53±0.02 0.68±0.02 0.75±0.01 F
15-year EFS±s.e. F F 0.74±0.01 F
5-year overall survival±s.e. 0.73±0.02 0.82±0.01 0.88±0.01 0.89±0.01
10-year overall survival±s.e. 0.68±0.02 0.78±0.01 0.85±0.01 F
15-year overall survival±s.e. F F 0.84±0.01 F
Abbreviations: ALL, acute lymphoblastic leukemia; CNS, central nervous system; EFS, event-free survival; NOPHO, Nordic Society of Paediatric
Haematology and Oncology; s.e., standard error.
aNo uniform definition of resistant disease before 1992 because of lack of uniform treatment strategies. Before 1992, the figures refer to patients
who died before remission. After 1992, resistant disease encompasses those that obtained remission only after shifting to alternative treatment
protocols.
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Delayed intensification. Patients with IR-, HR- or VHR-ALL
received delayed intensification with dexamethasone (10 mg/m2/
day for 3 weeks, then tapered), weekly VCR (2.0 mg/m2 four
times), weekly anthracycline (30 mg/m2/day Doxorubicin three
times (HR) or daunorubicin four times (IR)) and Erwinia
asparaginase (30.000 IU/m2 four times)4 followed by Cyclopho-
sphamide 1000 mg/m2, low-dose Cytarabine and 6-Thioguanine.
6-Mercaptopurine/methotrexate maintenance therapy. This
therapy was initiated at treatment weeks 13 (SR), 32 (IR) or 63
(HR) and continued until 2 (IR and HR) or 212 years (SR) after
diagnosis. During the first year of maintenance therapy, patients
with SR– or IR–ALL received alternate pulses at 4-week intervals
of (i) VCR (2.0 mg/m2 once) and Prednisolone (60 mg/m2/day for
1 week) and (ii) HD–MTX 5 g/m2/24 h with i.t. MTX and
Leucovorin rescue until five courses of HD–MTX had been
given. Every 8 weeks throughout maintenance therapy, HR
patients received reinductions of VCR (1.5 mg/m2 once) and
Prednisolone (40 mg/m2/day for 5 days) with i.t. MTX.
Hematopoietic stem cell transplantation (SCT). There
were no uniform Nordic criteria for SCT in the NOPHO ALL-92
protocol. In total, 57 patients (3.5%) underwent SCT in first
remission.
In addition to the inclusion of cranial irradiation for patients
with VHR–ALL, the primary therapeutic difference between the
HR and VHR protocol was the substitution of oral MTX/6MP
maintenance therapy (HR) with cyclic LSA2L2 maintenance
therapy (VHR).4,7 Furthermore, to examine whether a more
intensive cyclic multi-drug maintenance therapy regimen could
reduce the relapse rate for patients with higher risk features,
Finnish patients with higher risk features received LSA2L2
maintenance therapy irrespective of whether their induction/
consolidation/delayed intensification/CNS-directed therapy had
been according to the HR– or VHR–ALL regimens.7,23
Between 1992 and 1996, 538 patients with SR–, IR– or HR–
ALL entered into the randomized ALL-92 oral MTX/6MP
maintenance therapy trial. It examined the prognostic effect of
pharmacologically guided dose adjustments of oral 6MP/MTX
maintenance therapy by a combination of a target degree of
leukopenia and the erythrocyte levels of 6-Thioguanine nucleo-
tides (cytotoxic metabolites of 6MP) and MTX-polyglutamates
(the cytotoxic metabolites of MTX).6
NOPHO ALL-2000 risk grouping
The risk assignment features were very similar to that of the ALL-
92 protocol, except that (i) all children aged 1.0–9.9 years were
eligible to the SR-arm, if their WBC was o10 109/l and they
had no HR group features, (ii) t(1;19)(q23;p13), hypodiploidy
(o45 chromosomes) and all MLL-rearrangements were included
in higher risk features, and (iii) the higher risk group patients
were stratified into three treatment arms, that is, HR, VHR and
extra HR. Thus, patients who had higher risk features were
assigned to the VHR treatment arm, if they were at least 5 years
of age at diagnosis (because of the use of cranial irradiation in
that protocol arm) and in addition had WBC of 100–199 109/l,
and/or T-cell disease with mediastinal mass and/or CNS
leukemia. Patients with WBCX200 109/l, MLL-rearrangement
and age 410 years, hypodiploidy o34 chromosomes, translo-
cation t(9;22)(q34;q11), and/or a M3 bone marrow day 29, were
stratified to the extra HR group and offered allogeneic SCT in
first complete remission. Furthermore, it was optional to offer
SCT in first remission to patients with MRD levelsX103 after 3
months of antileukemic therapy. All other patients with higher
risk features were stratified to the HR–ALL group. In total, 62
patients (6.1%) were treated with SCT in first remission.
NOPHO ALL-2000 therapy
The NOPHO ALL-2000 therapy was a modification of the ALL-
92 treatment strategy.
Induction therapy was identical to that of the ALL-92 protocol
except that (i) one dose less of Doxorubicin was given, (ii) the
ceiling dose of VCR was set to 2.5 mg and (iii) Erwinase was
substituted with Escherichia coli asparaginase (6.500 IU/ at 3–4
days intervals, four times).
Consolidation therapy. The SR– and IR–ALL patients
received identical consolidation therapy starting treatment day
50 with 6MP (25 mg/m2/day) and alternating blocks with either
HD–MTX 5 g/m2/24 h with i.t. MTX (age adjusted) and
Leukovorin rescue 15 mg/m2 (three times) or low-dose cytar-
abine (75 mg/m2/day for 4 days, two times), whereas the
consolidation therapy for the higher risk patients was identical
to that of the ALL-92 protocol.
Delayed intensification. Patients with IR–, HR– or VHR–
ALL received delayed intensification similar to that of the ALL-
92 protocol except that (i) dexamethasone was given for 2 weeks
only (IR: 6 mg, higher risk 10 mg/m2/day), (ii) the maximum dose
of VCR was set to 2.5 mg and (iii) Erwinase was substituted with
E. coli asparaginase (6.500 IU/ at 3–4 days intervals, four times).
Irradiation. Before maintenance therapy, children above 5
years of age, who were allocated to the VHR group, received
18-Gy cranial irradiation (or 24 Gy in case of CNS leukemia at
diagnosis) with i.t. MTX weekly (three times) and oral 6MP
75 mg/m2. The dose of 6MP was reduced to 25 mg/m2 or to 5–
10 mg/m2 in case of one or two thioupurine methyltransferase
(TPMT) low activity alleles, respectively.24
LSA2L2 therapy. Courses of LSA2L2 therapy, identical to those
used in the NOPHO ALL-92 protocol were given two times (HR)
or three times (VHR) before the start of MTX/6MP maintenance
therapy, or until SCT could be performed (VHR–ALL).
Classical oral 6MP/MTX maintenance therapy. This
therapy was initiated at treatment weeks 17 (SR), 30 (IR), 70
(HR) or 61 (VHR) and continued until 2 (HR and VHR) or 212
years (SR and IR) from diagnosis. The starting dose of oral MTX
was 20 mg/m2, and the dose of oral 6MP was adjusted according
to the TPMT activity being 75 mg/m2/day for wild-type patients,
50 mg/m2/day for heterozygous patients and 5–10 mg/m2/day for
TPMT deficient patients. The doses of MTX and 6MP was
adjusted to a target WBC of 1.5–3.5 109/l. During the first year
of MTX/6MP maintenance therapy, patients with SR– or IR–ALL
received alternate pulses at 4-week intervals of (i) VCR (2.0 mg/
m2 once, maximum 2.5 mg) and dexamethasone (6 mg/m2/day
for 5 days) and (ii) HD–MTX 5 g/m2/24 h with i.t. MTX and
Leucovorin rescue until five courses of HD–MTX had been
given. Every 4 weeks throughout 6MP/MTX maintenance
therapy, HR and VHR patients received reinductions of VCR
(2.0 mg/m2 once, maximum 2.5 mg) and dexamethasone (6 mg/
m2/day for 5 days).
After the first year of maintenance therapy patients with SR–
or IR–ALL were randomized to either none or eight further
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reinductions with VCR (2.0 mg/m2 once, maximum 2.5 mg) and
dexamethasone (6 mg/m2/day for 5 days) at 6 weeks interval.
This study is still open for patient accrual and study results are
not reported here.
Statistical analysis
Survival analyses were performed with a basic time scale
defined by the date of diagnosis. The duration of event-free
survival (EFS) was defined as the time from diagnosis until the
date of induction failure, relapse, death or the development of a
second malignancy (whichever first) or the last known follow-up
for event-free survivors. Cases that did not attain a complete
remission were considered failures at time zero. For patients
who achieved complete remission, the cumulative risk of any
relapse, of isolated CNS or any (isolated plus combined) CNS
relapse, testicular relapse, therapy-related second malignancy or
of toxic death were estimated by the method of Kalbfleisch and
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Figure 1 Event-free survival (EFS) in four consecutive Nordic Society of Paediatric Haematology and Oncology (NOPHO) cohort periods.
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Figure 2 Overall survival in four consecutive Nordic Society of Paediatric Haematology and Oncology (NOPHO) cohort periods.
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Prentice, and outcomes were compared with Gray’s test,
adjusting for competing events. An isolated CNS relapse was
defined as a CNS relapse without relapse at other sites. A CNS
relapse included any relapse with CNS involvement. Cox
proportional hazards regression analyses were performed to
identify independent prognostic factors for differences in
outcome.25,26 Non-parametric methods were applied to com-
pare the distribution of parameters between subgroups.27 The
Kaplan–Meier method was applied for estimation of remission
duration and for the generation of survival curves.28 Two-sided
P-valueso0.05 were regarded as significant. The status of each
patient in the NOPHO leukemia registry is updated at least
annually. Within 10 years from the diagnosis of ALL (median:
6.7 years) 18 patients from the ALL-92 cohort were lost to
follow-up in the NOPHO ALL registry because of emigration
outside the Nordic countries (N¼ 3, median: 2.8 years), change
of Nordic address (N¼ 4, median: 5.2 years), transfer to an adult
department (N¼ 5, median: 6.8 years) or cessation of clinical
control or not otherwise specified (N¼ 6, median: 7.9 years).
Similarly, a total of eight patients from the ALL-2000 cohort
were lost to follow-up in the NOPHO ALL registry protocol at a
median of 2.5 years from diagnosis.
Results
Compared with the Nordic 10-years EFS results for the 1981–
1985 and 1986–1991 cohorts (52.9 and 68.3%, respectively),
the EFS improved significantly in the ALL-92 protocol
(74.6±1.1%) with indications of a further non-significant
improvement in the ALL-2000 protocol (Table 1). Today failures
very rarely occur beyond 10 years from diagnosis (o1%)
(Figure 1).
Protocol-specific treatment outcome
The NOPHO ALL-92: at 10 years, the EFS was 74.6±1.1% and
the overall survival was 84.7±0.9% for the 1645 evaluable
patients enrolled (Figures 1–3). The cumulative risk estimates for
isolated CNS and any CNS relapses were 2.6±0.4% and
4.8±0.5% at 5 years and 2.7±0.4% and 5.0±0.6% at 10
years, respectively (Figure 3). In spite of administration of CNS
irradiation, the cumulated risk of CNS relapse (combined or
isolated) among VHR–ALL patients was 9.3±2.3% with seven
of eight such cases having T-cell ALL and all being males.
Of the 889 male patients, 32 developed a testicular relapse
(isolated or combined with other relapse sites in 14 and 18
patients, respectively). The 5-year and 10-year risks for isolated
testicular relapse were both 0.7±0.2%.
Patients who relapsed had higher average neutrophil counts
(median: 2.2 vs 1.9 109/l, P¼ 0.0008) and WBC during
maintenance therapy (3.5 vs 3.3 109/l, P¼ 0.06) than those
who stayed in remission, but did not differ in their average
lymphocyte counts (P¼ 0.60).6 For both sexes, patients with an
average neutrophil count during maintenance therapy of
o2.0 109/l (median of all patients) had an EFS superior to
that of patients with higher average neutrophil counts (boys:
0.87 vs 0.75, P¼ 0.02, girls: 0.94 vs 0.83, P¼ 0.01).6
Furthermore, the risk of relapse was higher for the patients
who received MTX/6MP maintenance therapy and had normal
TPMT activity compared with those with reduced TPMT activity
(18 vs 7%, respectively P¼ 0.03).5 Patients stratified to
pharmacologically adjusted 6MP/MTX maintenance therapy
had an increased risk of relapse compared with those in the
conventionally treated control arm, however, this was only
statistically significant for girls (0.18±0.03 vs 0.05±0.02,
P¼ 0.002).6
For patients with HR– or VHR–ALL, administration of LSA2L2
maintenance therapy was related to a significantly increased risk
of relapse compared with that obtained with oral 6MP/MTX
maintenance therapy.7
In Cox multivariate regression analysis that also included
gender, age, WBC at diagnosis, immunophenotype and the
randomization groups, the average degree of myelosuppression
during maintenance therapy was significantly related to the risk
of relapse.6 Thus, patients who’s average leukocyte level during
maintenance therapy was below 3.5 109/l (protocol target)
had a significantly lower risk of relapse than the patients with
higher average leukocyte counts (0.14±0.02 vs 0.21±0.03,
P¼ 0.03).
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Figure 3 (a) Event-free survival (EFS), survival and cumulative
incidence of isolated or any central nervous system (CNS) relapse in
Nordic Society of Paediatric Haematology and Oncology (NOPHO)
acute lymphoblastic leukemia (ALL)-92 study. (b) EFS, survival and
cumulative incidence of isolated or any CNS relapse in NOPHO ALL-
2000 study.
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So far 21 second malignant neoplasms have been encoun-
tered on the ALL-92 protocol of which 16 were myelodysplasias
or acute myeloid leukemias.29 The cumulative risk of any
second malignant neoplasm was 1.1±0.3% at 10 years and
1.2±0.4% at 15 years, and that of second myeloid malignancies
plateaued at 1.1±0.3% at 7.5 years. The risk of developing a
Table 2 Treatment results according to presenting features of patients treated in NOPHO ALL-92 study
Factors No. of patients Event-free survival±s.e. (%) Overall survival±s.e. (%)
Year 5 Year 10 Year 15 P-value Year 5 Year 10 Year 15 P-value
B-lineage
NCI standard 1093 0.84±0.01 0.81±0.01 0.80±0.01 o0.001 0.93±0.01 0.91±0.01 0.89±0.01 o0.001
NCI high 376 0.65±0.03 0.63±0.03 0.63±0.03 0.81±0.02 0.76±0.02 0.75±0.02
T-lineage
NCI standard 35 0.69±0.08 0.69±0.08 0.69±0.08 0.44 0.74±0.07 0.74±0.07 0.74±0.07 0.362
NCI high 117 0.59±0.05 0.59±0.05 0.59±0.05 0.64±0.04 0.64±0.04 0.64±0.04
Sex
Male 889 0.75±0.01 0.72±0.02 0.71±0.02 0.009 0.87±0.01 0.84±0.01 0.82±0.01 0.168
Female 756 0.80±0.02 0.78±0.02 0.77±0.02 0.88±0.01 0.86±0.01 0.85±0.01
Age at diagnosis (years)
1–9 1378 0.79±0.01 0.76±0.01 0.75±0.01 0.004 0.89±0.01 0.86±0.01 0.85±0.01 o0.001
410 267 0.70±0.03 0.68±0.03 0.68±0.03 0.82±0.02 0.77±0.03 0.76±0.03
WBC 109/l
o10 838 0.82±0.01 0.78±0.01 0.78±0.01 o0.001 0.91±0.01 0.88±0.01 0.87±0.01 o0.001
10–49 516 0.81±0.02 0.79±0.02 0.77±0.02 0.91±0.01 0.88±0.01 0.86±0.02
50–99 139 0.66±0.04 0.65±0.04 0.64±0.04 0.79±0.03 0.75±0.04 0.75±0.04
4100 152 0.49±0.04 0.49±0.04 0.49±0.04 0.65±0.04 0.62±0.04 0.60±0.04
Cell lineage
BCP 1469 0.79±0.01 0.76±0.01 0.76±0.01 o0.001 0.90±0.01 0.87±0.01 0.85±0.01 o.0001
T 152 0.61±0.04 0.61±0.04 0.61±0.04 0.66±0.04 0.66±0.04 0.66±0.04
CNS status
CNS 1+2 1607 0.77±0.01 0.75±0.01 0.74±0.01 0.005 0.88±0.01 0.85±0.01 0.83±0.01 0.001
CNS 3 37 0.60±0.08 0.60±0.08 0.60±0.08 0.70±0.08 0.68±0.08 0.67±0.08
HeH; 450 chr
Yes 410 0.81±0.02 0.78±0.02 0.78±0.02 0.001 0.89±0.02 0.87±0.02 0.87±0.02 0.03
No 540 0.71±0.02 0.69±0.02 0.69±0.02 0.85±0.02 0.81±0.02 0.79±0.02
Unknown 695 0.80±0.02 0.77±0.02 0.76±0.02 0.89±0.01 0.86±0.01 0.85±0.01
DNA index
41.10 28 0.75±0.08 0.71±0.09 0.71±0.09 ns 0.93±0.05 0.85±0.07 0.85±0.07 ns
p1.10 33 0.70±0.08 0.66±0.09 0.66±0.09 0.82±0.07 0.78±0.08 0.78±0.08
Unknown 1584 0.77±0.01 0.75±0.01 0.74±0.01 0.88±0.01 0.85±0.01 0.84±0.01
t(9;22)
Present 32 0.44±0.09 0.41±0.09 0.41±0.09 o0.001 0.59±0.09 0.56±0.09 0.56±0.09 o0.001
Absent 919 0.76±0.01 0.74±0.01 0.74±0.01 0.88±0.01 0.85±0.01 0.83±0.01
Unknown 694 0.80±0.02 0.77±0.02 0.76±0.02 0.89±0.01 0.86±0.01 0.85±0.01
t(1;19)
Present 21 0.81±0.09 0.81±0.09 0.81±0.09 ns 0.95±0.05 0.90±0.07 0.90±0.07 ns
Absent 930 0.75±0.01 0.73±0.01 0.72±0.01 0.87±0.01 0.84±0.01 0.82±0.01
Unknown 694 0.80±0.02 0.77±0.02 0.76±0.02 0.89±0.01 0.86±0.01 0.85±0.01
t(12;21)
Present 174 0.80±0.03 0.76±0.03 0.75±0.04 ns (0.06) 0.94±0.02 0.90±0.02 0.83±0.05 0.01
Absent 589 0.73±0.02 0.72±0.02 0.72±0.02 0.85±0.01 0.82±0.02 0.81±0.02
Unknown 882 0.79±0.01 0.76±0.01 0.75±0.01 0.88±0.01 0.85±0.01 0.85±0.01
t(4;11)
Present 4 0.25±0.22 0.25±0.22 NA o0.01 0.25±0.22 0.35±0.22 NA 0.001
Absent 947 0.75±0.01 0.73±0.01 0.73±0.01 0.87±0.01 0.84±0.01 0.83±0.01
Unknown 694 0.80±0.02 0.77±0.02 0.76±0.02 0.89±0.01 0.86±0.01 0.85±0.01
Abbreviations: ALL, acute lymphoblastic leukemia; BCP, B-cell precursor; CNS, central nervous system; HeH, high-hyperdiploid leukemia; MRD,
minimal residual disease; NCI, National Cancer Institute risk assignment criteria; NOPHO, Nordic Society of Paediatric Haematology and Oncology;
s.e., standard error; WBC, white blood cell count.
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Table 3 Treatment results according to presenting features of patients treated in NOPHO ALL-2000 study
Factors No. of patients Event-free survival±s.e. (%) Overall survival±s.e. (%)
Year 5 Year 10 Year 15 P-value Year 5 Year 10 Year 15 P-value
B-lineage
NCI standard 645 0.85±0.02 F F o0.001 0.95±0.01 F F o0.001
NCI high 261 0.72±0.03 F F 0.82±0.03 F F
T-lineage
NCI standard 31 0.73±0.08 F F 0.24 0.79±0.08 F F 0.378
NCI high 84 0.61±0.05 F F 0.69±0.05 F F
Sex
Male 569 0.78±0.02 F F 0.36 0.89±0.02 F F 0.915
Female 454 0.81±0.02 F F 0.90±0.02 F F
Age at diagnosis (years)
1–9 840 0.81±0.02 F F 0.001 0.91±0.01 F F o0.001
410 183 0.71±0.04 F F 0.80±0.04 F F
WBC109/l
o10 154 0.84±0.02 F F o0.001 0.94±0.01 F F 0.0001
10–49 109 0.80±0.03 F F 0.90±0.02 F F
50–99 30 0.74±0.05 F F 0.84±0.04 F F
4100 65 0.63±0.05 F F 0.70±0.04 F F
Cell lineage
BCP 906 0.81±0.02 F F o0.001 0.91±0.01 F F o0.001
T 115 0.64±0.05 F F 0.72±0.0 F F
CNS status
CNS 1+2 990 0.80±0.02 F F 0.004 0.90±0.01 F F 0.018
CNS 3 30 0.63±0.10 F F 0.77±0.09 F F
HeH (450 chr)
Yes 321 0.84±0.02 0.08 0.93±0.02 ns
No 473 0.76±0.02 0.87±0.02
Unknown 229 0.80±0.03 0.89±0.02
DNA index
41.10 43 0.76±0.08 ns 0.90±0.05 ns
p1.10 93 0.76±0.05 0.88±0.04
Unknown 887 0.80±0.02 0.89±0.01
t(9;22)
Present 9 0.44±0.17 0.01 0.78±0.14 ns
Absent 786 0.79±0.02 0.89±0.01
Unknown 228 0.82±0.03 0.89±0.02
t(1;19)
Present 26 0.82±0.08 ns 0.87±0.07 ns
Absent 769 0.79±0.02 0.89±0.01
Unknown 228 0.81±0.03 0.89±0.02
t(12;21)
Present 201 0.86±0.03 o0.001 0.96±0.02 o0.001
Absent 666 0.77±0.02 0.88±0.01
Unknown 256 0.81±0.04 0.86±0.03
t(4;11)
Present 9 0.20±0.17 o0.001 0.36±0.19 o0.001
Absent 785 0.80±0.02 0.90±0.01
Unknown 229 0.80±0.03 0.89±0.02
MRD day 29
X5% 55 0.45±0.07 o0.001 0.60±0.08 o0.001
X0.1–o5% 195 0.74±0.04 0.90±0.03
o0.1% 497 0.86±0.02 0.93±0.01
No MRD analysis 276 0.77±0.01 0.87±0.01
Abbreviations: ALL, acute lymphoblastic leukemia; BCP, B-cell precursor; CNS, central nervous system; HeH, high-hyperdiploid leukemia; MRD,
minimal residual disease; NCI, National Cancer Institute risk assignment criteria; NOPHO, Nordic Society of Paediatric Haematology and Oncology;
s.e., standard error; WBC, white blood cell count.
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second malignant neoplasm was significantly related to oral
MTX/6MP maintenance therapy characteristics such as longer
duration of maintenance therapy, higher oral 6MP doses and
lower activity of TPMT, which leads to higher intracellular levels
of the cytotoxic 6-thioguanine nucleotides.29 The risk of second
malignant neoplasm was inversely related to the risk group,
being 2.4±0.7% for SR–ALL, 1.2±0.7% for IR–ALL and
0.3±0.3% for HR–ALL patients (P¼ 0.007).29
NOPHO ALL-2000. At 5 years, the EFS was 79.4±1.5%
and the overall survival was 89.1±1.1% for the 1023 evaluable
patients enrolled between 2002 and 2007 (Figures 1–3). The
cumulative risk estimates for isolated CNS and any CNS relapses
were 2.7±0.6 and 4.8±0.8% at 5 years (Figure 3). Of the 569
male patients only two have developed a testicular relapse, both
in combination with hematological relapse, with an overall 5-
year risk for testicular relapse of 0.2±0.2%. The randomized
study on the efficacy of VCR/dexamethasone will accrue
patients until mid 2009 and the results are still blinded.
Treatment results according to presenting features
Prognostic factors present at diagnosis were examined in
combined analyses of the NOPHO ALL-92 and ALL-2000
studies. High-risk B-lineage according to the NCI/Rome criteria
(ageo1 or410 years with leukocyte count450 109/l) and T-
cell phenotype were adverse prognostic factors during both
study periods (Tables 2 and 3).30
Male gender was associated with a reduced EFS in the ALL-92
protocol (75.4 vs 79.9 &, P¼ 0.009), whereas in the ALL-2000
protocol the outcome did not differ significantly for boys and
girls.
In univariate analysis, CNS disease at diagnosis (defined as
X5 106/l leukemic cells in the diagnostic spinal tap) was
related to a significantly increased risk of treatment failure
(Po0.01 in both study cohorts), but that was not the case if the
Cox regression analysis included T-cell immunophenotype and
WBC at diagnosis (P40.05 in both the ALL-92 and ALL-2000
cohorts).
The ETV6–RUNX1 translocation was linked to a favorable
prognosis in both the ALL-92 (Po0.001) and the ALL-2000
protocol (P¼ 0.06), primarily because of its strong association
with lower age and low leukocyte count,9,11 and it has not been
included in the risk grouping in the previous NOPHO studies or
the current NOPHO ALL-2008 protocol.
Except for MRD levelsX103 after 3 months of antileukemic
therapy being an optional indication for SCT in first remission in
the ALL-2000 study, MRD has not been used for treatment
stratification in the ALL-92 or the ALL-2000 studies. The ALL-
2000 study confirmed that the post-induction (day 29) MRD
levels is a strong independent prognostic factor for both EFS and
overall survival 16 (Table 3).
Discussion
The collaboration on risk-adapted treatment of childhood ALL
has within the last decades yielded almost identical survival
rates for the five Nordic countries (data not shown), which
overall now reach 88% at 5 years and 85% at 10 years. Later
events have become very rare, and non-CNS extramedullary
relapses now account for o5% of all events. However, the
overall recurrence rate of leukemia in the CNS, which was 4–
5% in both study ALL-92 and study ALL-2000, calls for further
improvement. The importance of CNS irradiation in first
remission has been questioned,31 and in a combined analysis
of the ALL-92 and ALL-2000 studies, the incidence of CNS
relapse was not significantly reduced, when CNS irradiation was
given to patients at the highest risk of this event (ageX10 years,
T-cell ALL, and/or WBCX50 109/l at diagnosis) (P¼ 0.63). To
reduce the risk of sequelae, no patients in the current ALL-2008
study will be exposed to CNS irradiation during first remission,
but we have added i.t. MTX at 8-week intervals during
maintenance therapy for patient with IR features, and we will
examine the efficacy and toxicity of i.t. Depocyte (liposomal
Cytarabine) in a randomized study for HR–ALL patients.32
Childhood leukemia are driven by mutations,33 but the
prognostic significance of the cytogenetic aberrations depends
Table 4 Risk grouping in NOPHO ALL-2008 study
Day 29 MRD Day 79 MRD
o0.1% 0.1–4.9% X5% o0.1% X0.1%
BCP and WBC o100 SR IR HR+SCT As day 29 risk group HR+SCT
T or WBCX100 IR HR HR+SCT As day 29 risk group HR+SCT
t(1;19)(q23;p13) IR IR HR+SCT As day 29 risk group HR+SCT
dic(9;20)(p13;q11) IR IR HR+SCT As day 29 risk group HR+SCT
ic21amp IR IR HR+SCT As day 29 risk group HR+SCT
CNS3 IR IR HR+SCT As day 29 risk group HR+SCT
Biphenotypic IR IR HR+SCT As day 29 risk group HR+SCT
Hypodiploidyo45 HR HR HR+SCT As day 29 risk group HR+SCT
MLL rearranged HR HR HR+SCT As day 29 risk group HR+SCT
Abbreviations: ALL, acute lymphoblastic leukemia; BCP, B-cell precursor; CNS, central nervous system; HR, high risk; IR, intermediate risk;
MRD, minimal residual disease; NOPHO, Nordic Society of Paediatric Haematology and Oncology; SCT, hematopoietic stem cell transplantation in
first remission; SR, standard risk; SR/IR/HR, standard, intermediate, high risk ALL; T-ALL, T-cell ALL; T/BCP, T-cell/B-cell precursor ALL; WBC,
white blood cell count.
MRD will be monitored by flow cytometry for BCP–ALL and by PCR (clonal antigen receptor rearrangements) for T-ALL; T/BCP; WBC 109/l;
SR/IR/HR; and SCT. The 4-week induction therapy with Vincristine, Doxorubicin, i.t. Methotrexate and a glucocorticosteroid
is identical for all patients except that patients with T-lineage and/or leukocyte count X100109/l receive Dexamethasone 10mg/m2/day for
3 weeks and all other patients receive Prednisolone 60mg/m2/day for 4 weeks. Translocation t(1;19)(q23;p13), dic(9;20)(p13;q11), intrachromosomal
amplification of chromosome 21,44 CNS leukemia (¼CNS3) at diagnosis, and bi-lineage or bi-phenotypic ALL always stratify patients to the IR
group, unless HR features are present. Hypodiploid ALL (o45 chromosomes) and MLL rearrangements always stratify patients to the HR group.
55% of all patients are projected to be allocated to the SR group, 35% to the IR group, and 10% to the HR group of whom half are projected to
receive a SCT in first remission. SR and IR patients will receive conventional ALL therapy, whereas HR–ALL patients as part of their treatment will
receive nine very intensive treatment blocks. The total duration of therapy will be 2.5 years for all non-SCT patients.
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on the treatment given and thus vary between study groups.
Some subsets such as translocation t(1;19)(q23;p13) and
dic(9;20)(p13;q11) have a high in vitro chemosensitivity,10,13
but may require relatively intensive chemotherapy to reduce
their risk of relapse, and in the NOPHO ALL-2008 protocol
these cytogenetic subsets are excluded from SR therapy. Other
subsets such as those with 11q23/MLL aberrations or a
hypodiploid clone (o45 chromosomes) do poorly in all
studies34,35 and should be offered very intensive chemotherapy.
Whether the latter two subsets will gain from hematopoietic SCT
remain to be shown, and in the NOPHO ALL-2008 protocol
these will be offered chemotherapy only (Table 4).35,36
Monitoring of MRD by PCR for clonal immune-gene
rearrangements or by flowcytometric identification of leukemic
cells with aberrant antigen expression has emerged as one of the
most powerful predictors of relapse.16,37,38 It allows early
modification of chemotherapy based on the in vivo response,
and it has emerged as a powerful tool to determine the efficacy
of early treatment phases.37,39 Stratification of patients by MRD
will allow identification of low-risk groups that can be cured by
less intensive therapy as well as resistant patients that can be
allocated to very intensive therapy with or without hemato-
poietic SCT. Although such stratification may improve the
balance between cure rates and toxicities within the risk groups,
it remains to be proven that this approach will improve the
overall cure rates of childhood ALL.
The treatment of ALL involves application of a specific
treatment protocol to a leukemic clone with specific mutations
that has emerged in a patient with a unique geno- and
phenotype. Accordingly, a large number of studies have shown
that inherited nucleotide sequence variations in genes involved
in absorption, metabolism, excretion, cellular transport and
targets or target pathways of antileukemic agents significantly
influence both the cure rate and individual risk of side effects.40
Thus, in addition to randomized trials and mapping of mutations
in the leukemic clones33 exploration of genome sequence
variations is expected to improve the understanding of the
mechanisms for both treatment failures and life-threatening
toxicities such as has been the case for polymorphisms in
TPMT.5,29 Accordingly, some studies have shown that the cure
rates or the degree of toxicity can be influenced by individua-
lization of therapy based on the patients drug disposition or
previous degree of toxicity.41,42
One of the important challenges for hematologists is to
improve the cure rates for adolescents and young adults to the
level of that obtained for children.43 To examine the biology of
their leukemias, their pharmacology, treatment efficacy and
pattern of side effects, as well as their compliance to therapy,
adult hematologists in Denmark, Norway and Sweden will treat
young adults between 18 and 45 years of age according to the
NOPHO ALL-2008 protocol.
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